Vascular Training Grant

这是耶鲁大学血管研究博士后T32的第四个竞争性更新申请。的 迄今为止，完成培训的研究员中，65%已获得学术教师职位和/或职业， 科学，许多人已经收到独立的赠款支持，计划成功的强有力的指标。的 持续的目标是提供实验室和转化研究培训高素质，多样化的医生 （医学博士）M.D.博士）和博士博士后研究员在血管生物学，在准备的职业生涯， 血管生物学和医学相关学科的独立研究者。培训生的选择将是 基于对血管生物学的承诺和强大的先前研究经验或潜力。 将鼓励临床和基础科学部门的申请，并在全国范围内进行竞争， 7年的槽。少数族裔申请人将通过多种途径专门征求。目前的38% 资助周期研究员是代表性不足的少数群体。培训将以导师为基础，还包括 咨询委员会和教学课程。培训的最短时间为2年。的 心血管医学部和耶鲁大学血管生物学和治疗学跨学科项目 将是这个项目的基础。一个关键的资产是耶鲁大学在血管生物学方面的跨学科优势。 参与教师的部门隶属关系包括心血管医学，免疫生物学， 药理学、病理学、遗传学、生物工程学、生理学、心胸外科学和计算 科学教师的选择是基于令人印象深刻的指导历史，正在进行的血管研究 生产力，强大的校外支持和承诺，作为导师在程序内。的实例 研究机会包括：（1）白细胞-内皮细胞的分子决定因素和后果 相互作用;（2）利用核和MR成像进行血管生成和血管重塑的分子成像 在动物模型中;（3）有助于血管发育的基因的定位和鉴定 人类疾病（动静脉畸形，冠状动脉疾病）;（4）血管工程 生物材料;（5）用于临床试验的血管生成基因调节剂的产生和（6）新的单细胞RNA 用于测定动脉粥样硬化促进细胞表型的序列分析方法。最后一 这些代表了新加入到我们计划中的顶级计算科学组件。这是一个广泛 一系列与疾病相关的血管研究，包括关键的翻译组成部分。培训生的进展将是 由每位导师、学员咨询委员会和项目联合主任监督。是 期望我们将培养未来的国家和国际领导人在血管研究。心血管 疾病是美国的主要死因，也是世界范围内死亡的主要原因。此程序将 为来自多个学科的不同个人提供重要机会，最终产生高影响力 努力降低心血管疾病的发病率，改善心血管疾病的结局。

This is the fourth competing renewal application for Yale University’s Vascular Research Postdoctoral T32. Of fellows who have completed training to date, 65% have obtained academic faculty positions and/or careers in science, and many have received independent grant support, strong indicators of program success. The continued goal is to provide laboratory and translational research training for highly qualified, diverse physician (M.D. and M.D./Ph.D.) and Ph.D. postdoctoral fellows in vascular biology, in preparation for careers as independent investigators in blood vessel biology- and medicine-related disciplines. Trainee selection will be based on a commitment to vascular biology and strong prior research experience or potential of same. Applications will be encouraged from clinical and basic science departments, with a nationwide competition for 7 yearly slots. Minority applicants will be specifically solicited through numerous avenues. 38% of the current funding cycle fellows are underrepresented minorities. The training will be mentor-based, also including advisory committees and didactic courses. The minimum duration of training will be 2 years. The Cardiovascular Medicine Division and Yale’s Interdisciplinary Program in Vascular Biology and Therapeutics will be the foundations for the program. A key asset is Yale’s interdisciplinary strength in vascular biology. Departmental affiliations for participating faculty include Cardiovascular Medicine, Immunobiology, Pharmacology, Pathology, Genetics, Bioengineering, Physiology, Cardiothoracic Surgery, and Computational Science. Faculty were chosen based on impressive histories of mentorship, ongoing vascular research productivity, strong extramural support and commitment to serve as mentors within the program. Examples of research opportunities include: (1) molecular determinants and consequences of leukocyte-endothelial cell interactions; (2) molecular imaging of angiogenesis and vascular remodeling utilizing nuclear and MR imaging in animal models; (3) mapping and identification of genes that contribute to the development of vascular disease (arterio-venous malformation, coronary artery disease) in humans; (4) engineering of vascular biomaterials; (5) generation of angiogenic gene regulators for use in clinical trials and (6) novel single cell RNA sequence analytic methods for determination of atherosclerosis-promoting cellular phenotypes. The last of these represents a top tier computational science component newly added to our program. This is a wide range of disease-related vascular research, with key translational components. Trainee progress will be monitored by each mentor, the trainee’s advisory committee and the Program Co-Directors. It is the expectation that we will train future national and international leaders in vascular research. Cardiovascular disease is the leading cause of death in the U.S., and a major cause of mortality world-wide. This program will provide important opportunities for diverse individuals from multiple disciplines to eventually lead high impact efforts at reducing the incidence of, and improving outcomes in, cardiovascular disease.